CCX-6569

N/A

Report date: 2025/01/26 19:30:32

NME

Base Information

Drug NameCCX-6569

Drug Alias NamePD-1/PD-L1 checkpoint inhibitor (ChemoCentryx)PD-1/PD-L1 immune checkpoint antagonist (Amgen)PD-1/PD-L1 immune checkpoint antagonist (ChemoCentryx)PD-1 checkpoint inhibitor/PD-L1 checkpoint inhibitor (ChemoCentryx)CCX-6569 (ChemoCentryx) +[7]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionProgrammed cell death protein 1 blockersProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1Programmed cell death protein 1

Therapy Area/IndicationsColonic NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesChemocentryx Inc

China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc

Inactive CompaniesChemocentryx Inc

Active IndicationsColonic Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A